Survodutide
Phase 3Peptide
Boehringer IngelheimSurvodutide is a peptide that works as a Glucagon/glp-1 Dual Agonist.[2] It is being investigated across 4 indications, with its most advanced program in Phase 3.[1]
Survodutide is one of 123 peptide programs targeting Kidney Disease. It is currently in Phase 3.
4
Indications
6
Total Trials
2
Active Trials
122
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
392 competitors in Obesity
#DrugCompanyPhaseTrials
1Survodutide
Boehringer IngelheimPhase 3
Actemra
RochePreclinical
Avapro
SanofiPreclinical
Colcrys
Alnylam PharmaceuticalsPreclinical
Amidate
PfizerPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Adenocard
AstellasPreclinical
Activella
Eli LillyPreclinical
Cetrotide
EMD SeronoPreclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Obesity2 trials
Overweight2 trials
Non-Alcoholic Steatohepatitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Survodutide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Glucagon/glp-1 Dual Agonist[2]
- Modality
- Peptide[2]
- Highest Phase
- Phase 3[1]
- Company